Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR3 | Q99500 | 11/20 | 0.60 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.47 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.47 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.47 |
| ▸ | SMYD3 | Q9H7B4 | 6/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21317622 | 0.95 | S1PR3 (0.63) | S1PR3S1PR1NPC1RAB9APSMB8 | |
| SCHEMBL2799191 | 0.95 | S1PR3 (0.63) | S1PR3S1PR1NPC1RAB9APSMB8 | |
| SCHEMBL2619062 | 0.93 | S1PR3 (0.55) | S1PR3S1PR1NPC1RAB9ASMYD3 | |
| Hydrochloric Acid SCHEMBL28161316 | 0.91 | S1PR3 (0.54) | S1PR3S1PR1NPC1RAB9ASMYD3 | |
| SCHEMBL2797162 | 0.86 | S1PR3 (0.55) | S1PR3S1PR1NPC1RAB9ASMYD3 | |
| SCHEMBL22554186 | 0.84 | S1PR3 (0.62) | S1PR3S1PR1NPC1RAB9APSMB8 | |
| SCHEMBL31643938 | 0.82 | S1PR3 (0.42) | S1PR3S1PR1NPC1RAB9ASMYD3 | |
| SCHEMBL892137 | 0.80 | S1PR3 (0.62) | S1PR3S1PR1NPC1RAB9APSMB8 | |
| SCHEMBL17619253 | 0.79 | S1PR3 (0.60) | S1PR3S1PR1NPC1RAB9APSMB8 | |
| SCHEMBL891863 | 0.79 | S1PR3 (0.65) | S1PR3S1PR1NPC1RAB9APSMB8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112088157-B | Aryl-bipyridylamine derivatives as phosphatidylinositol phosphokinase inhibitors | 拉文纳制药公司 | 2023-12-26 | — | — | CN | disclosed |
| EP-2376478-B1 | PYRIDYLOXYINDOLES INHIBITORS OF VEGF-R2 AND USE THEREOF FOR TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2017-04-19 | — | — | EP | disclosed |
| US-8501756-B2 | Heterobicyclic carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2013-08-06 | — | — | US | disclosed |
| US-8486954-B2 | Heterobicyclic carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2013-07-16 | — | — | US | disclosed |
| US-20130012529-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2013-01-10 | — | — | US | disclosed |
| US-20130005751-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2013-01-03 | — | — | US | disclosed |
| US-8242125-B2 | Heterobicyclic carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2012-08-14 | — | — | US | disclosed |
| US-20100168082-A1 | Heterobicyclic Carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005751-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | CDK2, PHKG1, PHKG2 | S1PR3 2755/4885S1PR1 2741/4885NPC1 4183/4885 |
| US-20100168082-A1 | Heterobicyclic Carboxamides as inhibitors for kinases | CDK2, PHKG1, PHKG2 | S1PR3 2755/4885S1PR1 2741/4885NPC1 4183/4885 |
| US-20130012529-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | CDK2, PHKG1, PHKG2 | S1PR3 2755/4885S1PR1 2741/4885NPC1 4183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.